International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.
about
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerThe role of orexin in post-stroke inflammation, cognitive decline, and depressionRole of the Orexin System on the Hypothalamus-Pituitary-Thyroid AxisDiscovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomniaDifferential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulatorsOrexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsSubstituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome.LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy.Attenuated orexinergic signaling underlies depression-like responses induced by daytime light deficiency.Integrating modern concepts of insomnia and its contemporary treatment into primary care.Suvorexant for the treatment of insomnia.The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis.Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep.The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice.The hypocretins and the reward function: what have we learned so far?A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats.Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators.Orexin, orexin receptor antagonists and central cardiovascular control.Discovery and development of orexin receptor antagonists as therapeutics for insomnia.Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism.The paraventricular nucleus of the thalamus is recruited by both natural rewards and drugs of abuse: recent evidence of a pivotal role for orexin/hypocretin signaling in this thalamic nucleus in drug-seeking behavior.Why does sleep stop migraine?Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?The hypocretin/orexin system: an increasingly important role in neuropsychiatry.Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.Orexin OX2 Receptor Antagonists as Sleep Aids.Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist.Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine.Hypothalamic dopaminergic neurons in an animal model of seasonal affective disorder.OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2 -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES.Putting migraine to sleep: Rexants as a preventive strategy.Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1).Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling.Orexin and Central Modulation of Cardiovascular and Respiratory Function.SB-334867, an orexin receptor 1 antagonist, decreased seizure and anxiety in pentylenetetrazol-kindled rats.
P2860
Q26746212-DF12B6F0-73FD-405A-BF70-CC035B8462B5Q26851982-F6ED9BCA-5A26-4256-B251-A9652783F961Q28069502-F28A1586-8F43-440B-AB40-A4863AE4EB3AQ28304842-DCA701AF-B8A8-4379-9A10-3B6EBD1BCE39Q30423240-5C857F70-D1D3-4E6B-BE13-ED2A7C7F6A80Q30437151-FBA461DD-5C54-456A-902B-842B9A12F3E3Q30486707-5A2AA138-D1DB-487F-9074-BDBF6391D68FQ30558573-D0DABEFB-AE60-4F57-B27D-CF7C179CB8D8Q30560872-3DA1B00E-542B-47AE-85E5-33BB90CB5E11Q30569599-644E7277-761B-48ED-89F8-360205E7E3D1Q33875477-6A860409-1F0A-4CF3-B984-881D8BDB1C7BQ34442421-182546B0-CA25-4344-BA8C-FBA532112B56Q34443676-A51F1B90-FF46-4466-98B3-7A9E0440503DQ34975026-4F716DB7-A67F-4B6F-B194-384361839C0AQ36394992-A672FD57-D335-415D-9C07-8154BC7B1A88Q36525478-C92249DB-C0AA-42EE-AC5E-327A186E7F9CQ36731312-8989FA13-3C63-463E-8E5E-05188F671B73Q36923729-72A52D7F-C6A4-4A86-97FF-5FBDD67C36E1Q37220464-7D4F900A-9C8B-43AC-AA9C-A36D1F2B4429Q37235803-BC2008CD-77A4-45D5-BC70-B5544AA35ECAQ37411777-AE2AFAC3-C253-412B-88C3-781DD94833BBQ37417966-277A1174-5435-493C-B150-AB42B9FE094EQ37522859-0FF113FB-78C4-45A3-B5EE-EA28C9062C25Q37583131-E0BE8F21-EBC2-43F8-88C8-9D7FB35EEADDQ37695281-5B6E17D5-7433-40CC-A0C3-59D4F51634B0Q38137751-3CA7B63A-37B0-4A4A-B00A-068CBA451744Q38221344-ACB498B0-95C0-4CD2-9CC4-2154893C9AC5Q38231949-F0B15C4B-7004-48FC-987A-D6CA2725681AQ38743165-E0A318C6-18CD-4F5A-A920-79C0FC21B787Q39026714-2EFB09CB-0C40-4028-A323-27B68AA91DE9Q39229046-04827FB4-F60F-45F0-B3FA-06D7AA274179Q41925736-F43DC479-C0D9-4BF8-850D-0473D7A44071Q42433431-87BB7FEF-0CEC-45F8-A38B-90CD8FEB345CQ43065862-B5804934-AC96-4AD9-AE21-7A11D11D3B95Q43762348-6D2137AA-92DB-4731-945B-B84C77274492Q47293244-6F803140-A549-4DC2-A505-7A2F36A28B4BQ47307899-3F7939C2-9D76-4935-A9D6-01B8F5BC5678Q47333843-896FC92B-13A9-40F8-82A0-4B164A74ABE6Q47357997-727B342D-9EEE-4411-B1DD-E924F3F7AE9DQ47385339-DD2011F1-5D93-4B3E-B0C0-16B952CB0E55
P2860
International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
International Union of Basic a ...... nomenclature and pharmacology.
@ast
International Union of Basic a ...... nomenclature and pharmacology.
@en
International Union of Basic a ...... nomenclature and pharmacology.
@nl
type
label
International Union of Basic a ...... nomenclature and pharmacology.
@ast
International Union of Basic a ...... nomenclature and pharmacology.
@en
International Union of Basic a ...... nomenclature and pharmacology.
@nl
prefLabel
International Union of Basic a ...... nomenclature and pharmacology.
@ast
International Union of Basic a ...... nomenclature and pharmacology.
@en
International Union of Basic a ...... nomenclature and pharmacology.
@nl
P2093
P356
P1476
International Union of Basic a ...... nomenclature and pharmacology.
@en
P2093
Andrea L Webber
Anthony L Gotter
John J Renger
Paul J Coleman
P304
P356
10.1124/PR.111.005546
P577
2012-07-01T00:00:00Z